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INTRODUCTION :
Incidences of diseases of milch animals is critical
to dairy industry imparting havoc economic thrust
in terms of veterinary and treatment costs, reduced
milk production in the subsequent lactation, milk
disposal due to antibiotic residues, early culling, extra
labour involvement and detoriation in  milk quality.
In order to avoid such circumstances, animals are
conventionally treated with antibiotics or vaccinated
against the particular disease. But with the emergence
of antibiotic resistant organisms, milk disposal due
to its residual effect to the end consumers, world-
wide concern for organic food production and ethi-
cal considerations of sufferings of animals has lim-
ited the antibiotic therapy.
Vaccination has also not been proved to be hun-
dred percent efficient against the diseases of multi-
etiological factors specially against diseases involv-
ing high morbidity rate. Thus, it seems understand-
ing and subsequent manipulation of the host immune
response (immune-modulation) is the most precise
and effective tool to lower down the disease
incidences and to nullify the limitations associated
with antibiotic treatment or vaccination.
The host defense system (immunity) is categori-
cally of two type i.e. non-specific or innate immu-
nity and specific immunity. Host immune response
represents a highly regulated yet integrated interac-
tion between different types of cells that respond to
eliminate the foreign invaders (pathogens). It is the
expression of the self for its own well being carried
out via an array of several interacting molecules. CD
(Cluster of Differentiation) molecules are one such
group, conferring self-defense to the host against
various pathogens. They are mostly found on vari-
ous differentiated cell type or types present in the
body. CD molecules ranges from 1 to 166 with dif-
ferential structure and functions (Goldsby et al.
2000), of these CD14 is the most important molecule
known so far, playing a vital role against several
endotoxigenic bacteria.
CD14 molecule :
Cluster of differentiation (CD) molecules are the
markers on the cell surface, as recognized by spe-
cific sets of antibodies, used to identify the cell type,
stage of differentiation and activity of a cell. The
CD nomenclature was proposed and established in
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was held in Paris in 1982. This system was intended
for the classification of many monoclonal antibod-
ies (mAbs), generated by different laboratories
around the world, against various surface molecules
(antigens) on leukocytes (white blood cells). Since
then, the use has expanded to many other cell types
and more than 250 CD clusters and sub-clusters have
been identified (Annon 2006b). CD14 molecule is
considered as 'pattern recognition molecule' in the
innate immune response against microorganisms and
other exogenous and endogenous stress factors. In
human, CD molecules range from 1 to 235 (Annon
2006b).
CD14, an anti bacterial peptide, binds and neu-
tralizes bacterial endotoxins. It is also known as 'my-
eloid membrane glycoprotein precursor' or 'LPS
receptor' and acts as an important mediator of innate
immunity. It has been classified as 'pattern recogni-
tion receptor', which binds LPS (Lipo-polysaccha-
ride) on gram-negative bacteria such as E. coli, Neis-
seria and Salmonella etc. facilitating the destruction
of microbes and induction for secretion of cytokines
involved in triggering adaptive immune response
(Tizzard 1998). CD14 is a phospho-inositol-glycan
linked cell surface receptor on macrophages that
binds to LPS. The core carbohydrate and lipidA of
LPS are virtually the same for these microbes and
hence become the target site for binding by CD14.
LPS can not act directly on cell by itself, rather binds
to CD14, a plasma protein that is also found on
neutrophils and monocytes. Each CD14 molecule
binds one or two LPS molecules, which is catalyzed
by LBP (Lipo-polysaccharide Binding Protein). Once
it binds with lipoproteins, the toxic activities of LPS
get lost. Apart from LPS, CD14 also binds to lipo-
arabinomannans of Mycobacteria, to manuronic acid
polymers of Pseudomonas sp. and to peptidoglycans
of Staphylococcus aureus. It is assumed to play a
key role in septic shock by interacting with mononu-
clear phagocytes and stimulating the macrophages
to secrete pro-inflammatory cytokines, IL-1, IL-6,
IL-12, TNF, several reactive oxygen species, nitro-
gen metabolites and arachidonic acid metabolites
including leukotrienes and prostaglandins, which in
turn destroy the pathogens (Tizzard 1998).The
polypeptide CD14 is of 40.076 kDa in human, where
as in bovine it is 46 kDa. The mature CD14 mem-
brane protein is composed of 356 amino acids with
4 sites for N-linked glycosylation. Additional 19
amino acid sequences are removed during process-
ing. CD14 is anchored to the cell surface by linking
with glycosyl-phosphatidyl-inositol (Wright  2006).
CD14 acts as a receptor for both LPS (Lipo-
polysacchaide) and peptidoglycan, two of the most
abundant constituents in the bacterial cell wall. CD14
functions both as a cell membrane receptor and a
soluble receptor for bacterial LPS. It has been re-
ported to bind to apoptotic cells (Deviit et al. 1998)
and phospholipids (Wang  et al. 1998). CD14 func-
tions as a receptor for endotoxin (LPS) (Wright et
al. 1990). LPS binds to LBP which facilitates the
binding of LPS to CD14 (Hailman et al. 1994).
Structure of CD14 molecule :
The primary structure of the bovine CD14 pro-
tein deduced from the DNA sequence consists of 374
amino acids. The first is methionine, followed by a
stretch of 15 hydrophobic and/or neutral residues,
typical of eukaryotic signal peptides. Alignment of
the amino acid sequences of bovine CD14 with hu-
man and mouse CD14 reveals 73.1% and 62.3%
identity, respectively (Julius et al. 2002). The
polypeptide CD14 is 40.076 kDa in human, whereas
it is 46 kDa in bovine. In human, the mature CD14
membrane protein is composed of 356 amino acids
with 4 sites for N-linked glycosylation. An additional
19 amino acid sequence is removed during process-
ing. CD14 is anchored to the cell surface by linkage
to glycosyl-phosphatidyl-inositol (Wright  2006).
Crystal structure of CD14 depicts a large hydro-
phobic pocket on the N-terminal side of the horse-
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polysaccharide binding map to the rim and bottom
of the pocket indicating that the main component of
the lipo-polysaccharide binding site. Mutations that
interfere with lipo-polysaccharide signaling but not
with lipo-polysaccharide binding, are also clustered
in a separate area near the pocket. Ligand diversity
of CD14 could be explained by the rim of the pocket,
the considerable flexibility of the rim of the pocket
and the multiplicity of grooves available for ligand
binding (Kim et al. 2005).
At least two soluble forms of CD14 (sCD14 ) have
been described. One soluble form is produced by
shedding from the cell surface, which results in an
approximately 48 kDa molecule (Bazil et al. 1986
& 1991, Hazoit et al. 1988 & 1993). A second solu-
ble form is released from cells before addition of the
GPI anchor at C-terminus, resulting in higher mo-
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ber of the family of  leucine rich proteins, with 10
leucine rich repeat motifs (LXXLXL), common to
both human and mouse CD14 (Ferrero et al. 1990).
First crystal structure of CD14 to 2.5 A0  resolution
has been identified (Kim et al. 2005).
Genetic characterization of CD14 gene :
Structure of CD14 gene:
CD14  gene  has been explored in various mam-
malian species including nucleotide sequencing of
genomic DNA  and  mRNA.
Chromosomal localization:
  CD14 gene has been mapped at various chro-
mosome locations in different species. It has been
found on Chromosome 18 in mouse (Ferrero et al.
1990) and rat. But in human and monkey, it is lo-
cated in chromosome 5. In bovine, it is mapped on
chromosome no. 7 (Gautier et al. 2003). In case of
dog, CD14 gene is mapped on chromosome number
2 (Gene card  2009).
Phylogenetic analysis of CD14 gene :
Crossbred cattle CD14 gene is 98.1, 96.0, 94.7,
90.5, 81.5, 81.1, 78.2, 78.1, 76.5, 70.6, 68.5, 59.3,
11.0%  identical to cattle(exotic, Bos taurus), buf-
falo, sheep, goat, pig, horse, human, dog, rabbit,
mouse, rat, monkey, chicken CD14 gene (Pal et al.
2011). Phylogenetic analysis reveals that cattle are
genetically most similar   to buffalo, followed by
sheep and goat (Pal et al. 2011,  Pal and Chatterjee
2009).
CD14 gene and its application in immuno-modu-
lation :
Characterization of CD14 gene is useful in vari-
ous ways of immuno-modulation-
I. Recombinant protein as antibacterial substance
against disease.
II.  Transgenic animal production with CD14 gene
insert.
III.  Somatic gene therapy against diseases.
IV. CD14 gene - used in marker assisted selec-
tion.
I. Recombinant protein as antibacterial substance
against disease:
The recombinant protein obtained from the
phenotypically resistant variety of CD14 gene, may
be of therapeutic use against a wide range of dis-
eases. Recombinant CD14 may be incorporated into
infant through feeding or incorporating CD14 as part
of a vaccination along with antigen. Recombinant
protein may also be administered to a patient having
T-cell immune deficiency and may also be used in
preparation of medicines for activating B-cells (Julius
et al. 2002).
  II. Transgenic animal production with CD14
gene insert :
Transgenic animals may also be produced with
the genetically resistant variant fragment of CD14
gene, to enhance disease resistance. The cloned gene
for CD14 can also be approached for somatic gene
therapy where, intramammary inoculation of CD14
gene construct may prove its worth against mastitis
(McBride  2002). Till now transgenic animals against
CD14 gene could not be produced, however studies
are in progress. Transgenic mice expressing
recombinant CD14 from cows have been produced
by ARS scientists Bob Wall. They will be challenged
with E. coli to see the worth of CD14 in mastitis
prevention. Eventually, bioengineered cows could be
developed with immunity to mastitis (McBride
2002). However, a transgenic cow with bacterial gene
insert of lysostaphin has been developed and is
claimed to be the first transgenic cow resistant to
mastitis (Suszkiw  2001).
107
CD 14 gene as a candidate gene for immunomodulationIII. Somatic gene therapy against diseases :
Somatic gene therapy with the gene inserted in
the tissue can be done with the aim of production of
protein locally, thus may be helpful for treating the
disease. The cloned gene for CD14 was designed
and inserted into a cow's mammary gland, so that
the protein was secreted only in milk. A delivery sys-
tem for insertion of CD14 gene construct through
intramammary route for the prevention of mastitis is
in progress (McBride  2002).
 In vivo transfection of mammary gland for the
production of high value protein against the patho-
gens known to be responsible for mastitis, had been
found to be effective and foreign protein production
into milk was observed 60 days after in vivo
transfection into lactating mammary gland of ewes
with plasmid DNA (Gagne et al. 1997).
IV. CD14  gene - used in marker assisted
selection :
Most of the economically important traits of live-
stock are complex, continuously distributed pheno-
types, influenced by environment and multiple
polygenes, remain dispersed across the genome.
Recent advances in molecular genetics have provided
rational basis for the expeditious improvement in
complex production traits. Thus, the immune re-
sponse genes especially the CD14 gene may be ex-
ploited for the benefit of mankind. The variability at
the nucleotide level of CD14 gene leads to the vari-
ability in the CD14 encoded molecule, which in turn
gives rise to the phenotypic variability in host im-
mune response. CD14 has been considered as an
important candidate gene for its association with
various diseases, like mastitis (Lee et al. 2003) in
dairy animals, treponemiasis (Schroder et al. 2000)
and glomerulo-nephritis (Yoon et al. 2003).  Genetic
polymorphism study for CD14   gene has been car-
ried out for the first time in any farm animal by us.
PCR-SSCP study on CD14 gene has been carried
out in buffalo, where eight variants have been iden-
tified (Pal et al. 2008b, Pal and chatterjee 2006, Pal
and chatterjee 2010      Gen bank accession no.
EU370398 to EU370403 ). Association of these vari-
ants with economic traits may lead to establishment
of marker. Thus, the variants of CD14 gene and their
association with the incidences of disease occurrence
may be used as a marker for disease resistance. Simi-
lar association studies have been conducted with
other genes as growth hormone gene (Pal et al.  2004,
Pal et al. 2005).This nucleotide variation can be di-
agnosed by RFLP/SSCP assay and the markers as-
sociated with these quantitative trait loci can be ap-
plied as an alternative selection strategy for augment-
ing disease resistance trait. This is of prime impor-
tance for the cases where the traits of interest have
Fig 1: Molecular characterization of CD14 gene in goat
depicted in 1% agarose gel electrophoresis.  Lane 1, 2,
3 represents amplified product of caprine CD14 gene.
(Source: Pal et al. 2009. Journal of  Small Ruminant
Research. 82: 84-87)
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late in life. Marker assisted selection (MAS) allows
to select the individuals at an early age, independent
of its sex. Besides, it also yields a rapid genetic
progress than other conventional methods and yet
remains sustainable.
With the recent molecular techniques it can be
exploited as a therapeutic agent (recombinant prod-
uct or DNA construct), development of disease re-
sistant transgenics and strategic breeding practises
(MAS).
 CONCLUSION :
CD14 gene   is an important gene for immuno-
modulation. CD14 molecule and CD14 gene has been
characterized in various livestock species. Structural
analysis of CD14 molecule and CD14 gene encod-
ing it is helpful for understanding its function for
immuno-modulation. CD14 gene has been observed
to be highly variable both between and within spe-
cies, which may be helpful for biodiversity and evo-
lutionary studies. There is a need to ascertain the
differential biological potency of different allelic
variations of CD14. On the basis of such functional
study, the most potent variant can be expressed in
vitro for further therapeutic/immunological or im-
mune-competence study. Future scope includes dis-
ease resistant transgenic animal production with re-
sistant variety of CD14 gene insert and somatic gene
therapy. Marker assisted selection may be helpful
for a breeder for selection of disease resistant ani-
mals at an early age.  The above methods need to be
commercialized and applied in field conditions for
the ultimate benefit to the farmers.
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